Diferencia entre revisiones de «H1N1 (swine) flu»
m (Mholtz moved page H1N1 (Swine) Flu to H1N1 (swine) flu) |
|||
| (No se muestran 3 ediciones intermedias de 2 usuarios) | |||
| Línea 1: | Línea 1: | ||
==Background== | ==Background== | ||
===High-risk groups=== | ===High-risk groups=== | ||
*Pregnant- | *Pregnant- increased rates of SAB, preterm labor | ||
*Chronic lung disease | *Chronic lung disease | ||
*Immunosuppressed | *Immunosuppressed | ||
*Cardiac | *Cardiac | ||
* | *[[Diabetes mellitus]] | ||
===Screening=== | ===Screening=== | ||
| Línea 17: | Línea 17: | ||
== | ==Evaluation== | ||
*Rapid Flu nasal swab 60-80% sensitive in detecting influenza A | *Rapid Flu nasal swab 60-80% sensitive in detecting influenza A | ||
**If patient is negative, severely ill and will be hospitalized, send viral culture | **If patient is negative, severely ill and will be hospitalized, send viral culture | ||
| Línea 23: | Línea 23: | ||
==Management== | ==Management== | ||
*Adult: Tamiflu 75-mg capsule twice per day for 5 days | *Adult: [[Tamiflu]] 75-mg capsule twice per day for 5 days | ||
**All hospitalized patients with confirmed, probable or suspected novel influenza (H1N1) | **All hospitalized patients with confirmed, probable or suspected novel influenza (H1N1) | ||
**Patients who are at higher risk for seasonal influenza complications | **Patients who are at higher risk for seasonal influenza complications | ||
| Línea 30: | Línea 30: | ||
===Post-exposure chemoprophylaxis=== | ===Post-exposure chemoprophylaxis=== | ||
*Tamiflu 75mg PO daily x 10 days (10 days after the last known exposure to novel (H1N1) influenza) | *[[Tamiflu]] 75mg PO daily x 10 days (10 days after the last known exposure to novel (H1N1) influenza) | ||
''If the contact occurred with a patient after 7 days of | ''If the contact occurred with a patient after 7 days of symptom onset, then chemoprophylaxis is not necessary. This is the presumed post-infectious period.'' | ||
==Disposition== | ==Disposition== | ||
Revisión actual - 00:11 26 feb 2017
Background
High-risk groups
- Pregnant- increased rates of SAB, preterm labor
- Chronic lung disease
- Immunosuppressed
- Cardiac
- Diabetes mellitus
Screening
- Individuals with an acute febrile respiratory illness (a measured temperature of 100ºF or higher and recent onset of at least one of the following: rhinorrhea, nasal congestion, sore throat, or cough) or sepsis-like syndrome.
- HIGH PRIORITY for hospitalized patients and those at high-risk for severe disease.
Clinical Features
Differential Diagnosis
Evaluation
- Rapid Flu nasal swab 60-80% sensitive in detecting influenza A
- If patient is negative, severely ill and will be hospitalized, send viral culture
- PCR is the recommended confirmatory test
Management
- Adult: Tamiflu 75-mg capsule twice per day for 5 days
- All hospitalized patients with confirmed, probable or suspected novel influenza (H1N1)
- Patients who are at higher risk for seasonal influenza complications
Most effective when started within 48 hours of illness onset.
Post-exposure chemoprophylaxis
- Tamiflu 75mg PO daily x 10 days (10 days after the last known exposure to novel (H1N1) influenza)
If the contact occurred with a patient after 7 days of symptom onset, then chemoprophylaxis is not necessary. This is the presumed post-infectious period.